View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ABGSC Energy Research ... (+7)
  • ABGSC Energy Research
  • Daniel Vårdal Haugland
  • Herman Caspersen
  • John Olaisen
  • Lars Trongaard Brattli
  • Martin Mauseth
  • Stian Wibstad
David Barden ... (+2)
  • David Barden
  • Vikash Harlalka

Broadband cNPS comparisons by tech & operator - The latest data availa...

Scouring the data in this report, we’d point you to the appendix for a quick review. What stands out is that when a broadband customer interacts with a sales rep, presumably they are doing so with a problem or request that an automated or AI-driven IVR cannot address. Almost without fail, sales rep interactions are the Achilles heal of the market right now and likely a core reason, care scores suffer. The operator that can solve this puzzle, and it could be cable, has a window to shift their rel...

Lumen Technologies, Inc.: Update to credit analysis following upgrade ...

Our credit view of Lumen reflects improved credit metrics, very good liquidity and steady progress in operating efficiency offset by improving but still negative revenue trends until 2028

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 7, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) VANCOUVER, Wash. and NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on March 3, 2026, the company granted a non-statutory stock option to purchase an aggregate of 650,000 shares of its common stock to Dr. Ransi Somaratne in connection with his employment as Absci’s Chief Medical Officer. The inducement grant was previously approved by the Compensation Committee ...

FMC Corp: 1 director

A director at FMC Corp bought 18,072 shares at 13.830USD and the significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

David Barden ... (+2)
  • David Barden
  • Vikash Harlalka

Broadband Spring 2026 – A fine time for FWA

In this Broadband Spring report, we share a quick update on broadband industry trends from 4Q25 heading into 2026E. Industry net adds improved meaningfully in 4Q25 from a year ago but remained slightly below last year when we adjust for the loss of ACP. Net adds for the quarter were in line with the pre-pandemic norm but trailing twelve-month net adds remain below pre-pandemic levels. We take a deep-dive here into FWA’s continued strong momentum, by carrier, and how it fits into the overall broa...

 PRESS RELEASE

Absci Strengthens Clinical Leadership with Appointment of Ransi Somara...

Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer Former Vertex executive to spearhead the clinical development of Absci’s expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci’s Scientific Advisory Board VANCOUVER, Wash. and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the app...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 28, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 27, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Gogo Announces Fourth Quarter and Full Year 2025 Results

Gogo Announces Fourth Quarter and Full Year 2025 Results Total Q4 Revenue of $230.6 million, up 67% Year-over-Year; Service Revenue of $191.9 million, up 61% Year-over-Year  Full Year Results at High End of 2025 Guidance Range for Revenue, Adjusted EBITDA and Free Cash Flow Gogo Galileo and 5G Expected to Ramp in 2026 Company Provides 2026 Financial Guidance BROOMFIELD, Colo., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Gogo Inc. (NASDAQ: GOGO) (“Gogo” or the “Company”), a leading global provider of broadband connectivity services for the business and military/government aviation markets, tod...

 PRESS RELEASE

AMN Healthcare Survey Reveals Sharp Divide Between Leaders’ Organizati...

AMN Healthcare Survey Reveals Sharp Divide Between Leaders’ Organizational Confidence and Industry Outlook for 2026 Survey of 700+ executives shows AI leadership roles surging as succession planning and clinician engagement lag DALLAS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- While nearly three-quarters of healthcare executives believe their own organizations will be as strong or stronger in 2026, more than half expect the healthcare industry overall to face a worse year ahead, according to a new survey of healthcare executives. The findings highlight a widening confidence gap alongside a rapi...

David Barden
  • David Barden

Lumen investor day takeaways…all better now?

Mission accomplished! Lumen’s turnaround is complete. This was the message at the 2/25 Lumen analyst day we attended in NYC, its first since CEO Kate Johnson joined 11/22. The 3 pillars supporting this claim include 1) the balance sheet is finally fixed. No small feat, but achieved at the cost of selling hard won FTTH assets at a discount to AT&T and mortgaging future services revenue in exchange for up-front construction PCF cash. 2) and 3) are changing out people and fixing on a strategy to be...

 PRESS RELEASE

Absci to Report Business Updates and Fourth Quarter and Full Year 2025...

Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026 VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2025 after market close on Tuesday, March 24, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m....

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch